Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):444–450. doi: 10.1038/bjc.1990.315

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

S Marsoni 1, V Torri 1, M G Valsecchi 1, C Belloni 1, U Bianchi 1, G Bolis 1, C Bonazzi 1, N Colombo 1, A Epis 1, G Favalli 1, et al.
PMCID: PMC1971438  PMID: 2119684

Abstract

The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnitude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7-25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based regimens were associated to an overall prolonged median survival, but this benefit was not observable in the subgroup with most favourable prognosis (less than 2 cm residual tumour size). The implications of these observations for clinical research and ovarian cancer patients care are discussed.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell D. R., Woods R. L., Levi J. A., Fox R. M., Tattersall M. H. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. Aust N Z J Med. 1982 Jun;12(3):245–249. doi: 10.1111/j.1445-5994.1982.tb02469.x. [DOI] [PubMed] [Google Scholar]
  2. Bertelsen K., Jakobsen A., Andersen J. E., Ahrons S., Pedersen P. H., Kiaer H., Arffmann E., Bichel P., Boestofte E., Strøyer I. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol. 1987 Oct;28(2):161–169. doi: 10.1016/0090-8258(87)90210-1. [DOI] [PubMed] [Google Scholar]
  3. Bolis G., Bortolozzi G., Carinelli G., D'Incalci M., Gramellini F., Morasca L., Mangioni C. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study. Cancer Chemother Pharmacol. 1980;4(2):129–132. doi: 10.1007/BF00254034. [DOI] [PubMed] [Google Scholar]
  4. Burslem R. W., Wilkinson P. M. Treating ovarian cancer. Br Med J (Clin Res Ed) 1986 Oct 18;293(6553):972–973. doi: 10.1136/bmj.293.6553.972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carmo-Pereira J., Costa F. O., Henriques E. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1983;10(2):100–103. doi: 10.1007/BF00446218. [DOI] [PubMed] [Google Scholar]
  6. Conte P. F., Bruzzone M., Chiara S., Sertoli M. R., Daga M. G., Rubagotti A., Conio A., Ruvolo M., Rosso R., Santi L. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 1986 Jun;4(6):965–971. doi: 10.1200/JCO.1986.4.6.965. [DOI] [PubMed] [Google Scholar]
  7. Decker D. G., Fleming T. R., Malkasian G. D., Jr, Webb M. J., Jeffries J. A., Edmonson J. H. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481–487. [PubMed] [Google Scholar]
  8. Dembo A. J. Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data. J Clin Oncol. 1986 Nov;4(11):1573–1576. doi: 10.1200/JCO.1986.4.11.1573. [DOI] [PubMed] [Google Scholar]
  9. Griffiths C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct;42:101–104. [PubMed] [Google Scholar]
  10. Mangioni C., Bolis G., Pecorelli S., Bragman K., Epis A., Favalli G., Gambino A., Landoni F., Presti M., Torri W. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464–1471. doi: 10.1093/jnci/81.19.1464. [DOI] [PubMed] [Google Scholar]
  11. Mastrangelo R., Poplack D., Bleyer A., Riccardi R., Sather H., D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol. 1986;14(3):191–194. doi: 10.1002/mpo.2950140317. [DOI] [PubMed] [Google Scholar]
  12. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Vriesendorp R., Kooyman C. D., van Lindert A. C., Hamerlynck J. V., van Lent M., van Houwelingen J. C. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594–600. doi: 10.1016/s0140-6736(84)90594-4. [DOI] [PubMed] [Google Scholar]
  13. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  14. Omura G. A., Morrow C. P., Blessing J. A., Miller A., Buchsbaum H. J., Homesley H. D., Leone L. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983 Mar 1;51(5):783–789. doi: 10.1002/1097-0142(19830301)51:5<783::aid-cncr2820510506>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  15. Omura G., Blessing J. A., Ehrlich C. E., Miller A., Yordan E., Creasman W. T., Homesley H. D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 1;57(9):1725–1730. doi: 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  16. Redman J. R., Petroni G. R., Saigo P. E., Geller N. L., Hakes T. B. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 1986 Apr;4(4):515–523. doi: 10.1200/JCO.1986.4.4.515. [DOI] [PubMed] [Google Scholar]
  17. Richardson G. S., Scully R. E., Nikrui N., Nelson J. H., Jr Common epithelial cancer of the ovary (2). N Engl J Med. 1985 Feb 14;312(7):415–424. doi: 10.1056/NEJM198502143120706. [DOI] [PubMed] [Google Scholar]
  18. Sessa C., Bolis G., Colombo N., D'Incalci M., Mermillod B., Valente I., Mangioni C. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial. Cancer Chemother Pharmacol. 1985;14(3):222–228. doi: 10.1007/BF00258120. [DOI] [PubMed] [Google Scholar]
  19. Swenerton K. D., Hislop T. G., Spinelli J., LeRiche J. C., Yang N., Boyes D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985 Feb;65(2):264–270. [PubMed] [Google Scholar]
  20. Tomirotti M., Perrone S., Giè P., Canaletti R., Carpi A., Biasoli R., Lombardi F., Giovanninetti A., Mensi F., Villa S. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial. Tumori. 1988 Oct 31;74(5):573–577. doi: 10.1177/030089168807400514. [DOI] [PubMed] [Google Scholar]
  21. Wilbur D. W., Rentschler R. E., Wagner R. J., Keeney E. D., King A., Hilliard D. A. Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. J Surg Oncol. 1987 Mar;34(3):165–169. doi: 10.1002/jso.2930340306. [DOI] [PubMed] [Google Scholar]
  22. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]
  23. Wittes R. E., Friedman M. A. Accrual to clinical trials. J Natl Cancer Inst. 1988 Aug 17;80(12):884–885. doi: 10.1093/jnci/80.12.884. [DOI] [PubMed] [Google Scholar]
  24. Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES